Welcome to our dedicated page for Alto Neuroscience SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alto Neuroscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alto Neuroscience's regulatory disclosures and financial reporting.
BlackRock, Inc. reports beneficial ownership of common stock of Alto Neuroscience Inc. BlackRock and certain of its business units hold 2,104,406 shares of Alto Neuroscience common stock, representing 6.0% of the class.
BlackRock has sole voting power over 2,077,542 shares and sole dispositive power over 2,104,406 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Alto Neuroscience’s outstanding common shares.
Alto Neuroscience, Inc. has a significant shareholder group led by EcoR1 Capital. EcoR1 Capital, LLC and its control person, Oleg Nodelman, each report beneficial ownership of 2,232,000 shares of Alto Neuroscience common stock, representing 5.8% of the class. EcoR1 Capital Fund Qualified, L.P. reports beneficial ownership of 2,065,935 shares, or 5.3% of the common stock. These percentages are calculated using 38,829,167 shares outstanding following the closing of an offering described in a July 14, 2026 prospectus. The reporting persons have no sole voting or dispositive power over the shares but share voting and dispositive power in the amounts reported. They state that the securities were acquired and are held without the purpose or effect of changing or influencing control of Alto Neuroscience.
Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, as representative of several underwriters, to issue and sell 3,776,436 shares of common stock in an underwritten registered direct offering under an effective shelf registration statement. The shares are priced at $26.48 per share, and the company estimates net proceeds of approximately $93.9 million after underwriting discounts, commissions and offering expenses.
The closing is expected on July 14, 2026, subject to customary conditions. Alto Neuroscience plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital.
Alto Neuroscience, Inc. is conducting a primary underwritten offering of 3,776,436 shares of common stock at $26.48 per share, for an aggregate offering price of $100,000,025.28. Underwriting discounts are $1.4564 per share, yielding $94,500,023.89 in proceeds before expenses and estimated net proceeds of approximately $93.9 million.
The company plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including an additional planned Phase 3 monotherapy trial in treatment resistant depression, and for general working capital purposes.
Cash, cash equivalents and restricted cash were preliminarily estimated at $244.2 million as of June 30, 2026. Shares outstanding are expected to increase from 35,052,731 as of March 31, 2026 to 38,829,167 after the offering, which the company calculates will result in immediate dilution of $17.80 per share to new investors relative to the adjusted net tangible book value.
Alto Neuroscience, Inc. reported a preliminary estimate of its cash, cash equivalents and restricted cash of approximately $244.2 million as of June 30, 2026. This figure is based on management’s estimates, has not been audited, reviewed or compiled by the independent registered public accounting firm, and may change after completion of accounting procedures for the quarter ended June 30, 2026; any differences may be material.
The company also outlined a pipeline update, stating that it intends to accelerate and expand clinical development of its ALTO-207 program, including conducting an additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
Alto Neuroscience, Inc. director Andrew Craig Miller received a grant of stock options covering 26,000 shares of common stock at an exercise price of $20.44 per share. These options vest in 36 equal monthly installments starting on June 27, 2026, and were awarded under the company’s Non-Employee Director Compensation Policy, with no cash paid by the director for the grant.
Alto Neuroscience, Inc. director Andrew Craig Miller filed an initial Form 3 reporting his status as a director of the company. The excerpt shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this filing.
Alto Neuroscience, Inc. appointed Andrew Miller, Ph.D. to its Board of Directors as a Class III director, filling a seventh board seat for a term ending at the 2027 annual stockholder meeting. He was also named to the Nominating and Corporate Governance Committee and deemed independent under NYSE and SEC rules.
As a non-employee director, Dr. Miller will receive an initial stock option for up to 48,200 shares or options valued at up to $400,000 by Black‑Scholes, plus ongoing annual option grants and cash retainers for board and committee service under the company’s Non-Employee Director Compensation Policy.
Alto Neuroscience, Inc. President and CEO Amit Etkin reported a bona fide gift of 400,000 shares of Common Stock on May 14, 2026. The shares were transferred for estate planning purposes to the Bard on Haven Trust, an irrevocable trust for the benefit of his spouse and children, for no consideration. The trustee is independent, and Etkin has no voting, dispositive, or pecuniary interest in the trust’s holdings. After the gift, he directly holds 833,949 shares of Alto Neuroscience common stock.
Alto Neuroscience, Inc. Amendment No. 1 to a Schedule 13G/A reports that Vestal Point Capital and affiliated reporting person Ryan Wilder beneficially hold 2,064,075 shares of Common Stock, representing 6.5% of the class. The filing cites 31,945,516 shares outstanding as of March 9, 2026 as the basis for the percentage. The statement lists shared voting and dispositive power over the 2,064,075 shares and provides the reporters' business address and CUSIP 02157Q109. The filing is signed by Ryan Wilder on behalf of Vestal Point Capital, LLC and individually with signature dates of 05/15/2026.